Open AccessResults of Gemaza therapy of hemophthalmia in patients with diabetic retinopathy
Author(s) -
Nargiza Normatova,
Норматова Наргиза Миршавкатовна
Publication year - 2010
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-5683
Subject(s) - medicine , diabetic retinopathy , visual acuity , diabetes mellitus , ophthalmology , retinopathy , surgery , endocrinology
Aim. To evaluate efficiency of Gemaza used to treat hemophthalmia of different severity and localization. Materials and methods. Gemaza (5000 IU) was admnistered parabulbarly to 75 patients (78 eyes) with diabetes mellitus (DM) after dilution in0.5 ml of 0.9% sodium chloride solution. Each patient received 10 daily injections during baseline hypoglycemic therapy. Control group was comprisedof 20 patients (20 eyes) with hemophthalmia, treated by traditional drug therapy (emoxipin, dicinon, ascorutin, actovegin). Results. Gemaza proved a highly efficient agent showing hemoresorptive and fibrinolytic activities; it improved visual acuity in 51.3% of the patientsfrom day 5 after the onset of therapy. Conclusion. It is recommended to administer Gemaza soon after hemorrhage, prior to the development of proliferative processes in the vitreous bodyand retina.